SMARCD3/BAF60C Antibody [C13A4] | Primary Antibodies

Application: Reactivity: Human, Mouse, Rat, Monkey

Usage Information

Dilution
WB1:1000 IP1:100

Application
WB, IP

Reactivity
Human, Mouse, Rat, Monkey

Source
Rabbit Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW
60 kDa

Datasheet & SDS

Biological Description

Specificity
SMARCD3/BAF60C Antibody [C13A4] detects endogenous levels of total SMARCD3/BAF60C protein.

Clone
C13A4

Synonym(s)
SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily D member 3; 60 kDa BRG-1/Brm-associated factor subunit C; BRG1-associated factor 60C (BAF60C); SMARCD3; BAF60C

Background
SMARCD3, also known as BAF60c, is a core subunit of the mammalian SWI/SNF (BAF) ATP-dependent chromatin remodeling complex that enables nucleosome repositioning and gene activation by stabilizing interactions between the BRG1 or BRM ATPase and transcription factors during development and metabolism. This protein, which is about 530 amino acids long, contains two SWI3-like ATPase-association domains that bind the ATPase motor non-covalently, flanked by intrinsically disordered regions that allow for modular assembly into canonical BAF, neural progenitor BAF (npBAF), or specialized lipoBAF complexes with ARID1A or ARID1B, SS18, and tissue-specific partners. SMARCD3's primary function is to integrate signals from nuclear receptors such as RAR, PPAR gamma, and LXR, as well as lineage transcription factors like FOXA1, recruiting SWI/SNF to enhancers and promoters to slide or evict nucleosomes, deposit active histone marks like H3K27 acetylation, and drive transcription of genes involved in skeletal and cardiac muscle differentiation, lipogenesis through SREBP1, ACC, and FASN, glucose homeostasis via DEPTOR-AKT signaling, and epithelial-mesenchymal transition. In the lipoBAF complex, SMARCD3 senses feeding and insulin signals to remodel chromatin at lipogenic gene loci, increasing triglyceride production and repressing catabolic pathways, while in heart and muscle tissue, it partners with GATA4 and MEF2C to regulate genes essential for sarcomere and cytoskeletal organization during congenital morphogenesis. Dysregulation of SMARCD3 contributes to medulloblastoma dissemination, especially in Group 3 tumors through Reelin and H3K27 trimethylation, pancreatic cancer therapy resistance, abdominal aortic aneurysms, and poor outcomes across various solid tumors.

Background

SMARCD3, also known as BAF60c, is a core subunit of the mammalian SWI/SNF (BAF) ATP-dependent chromatin remodeling complex that enables nucleosome repositioning and gene activation by stabilizing interactions between the BRG1 or BRM ATPase and transcription factors during development and metabolism. This protein, which is about 530 amino acids long, contains two SWI3-like ATPase-association domains that bind the ATPase motor non-covalently, flanked by intrinsically disordered regions that allow for modular assembly into canonical BAF, neural progenitor BAF (npBAF), or specialized lipoBAF complexes with ARID1A or ARID1B, SS18, and tissue-specific partners. SMARCD3's primary function is to integrate signals from nuclear receptors such as RAR, PPAR gamma, and LXR, as well as lineage transcription factors like FOXA1, recruiting SWI/SNF to enhancers and promoters to slide or evict nucleosomes, deposit active histone marks like H3K27 acetylation, and drive transcription of genes involved in skeletal and cardiac muscle differentiation, lipogenesis through SREBP1, ACC, and FASN, glucose homeostasis via DEPTOR-AKT signaling, and epithelial-mesenchymal transition. In the lipoBAF complex, SMARCD3 senses feeding and insulin signals to remodel chromatin at lipogenic gene loci, increasing triglyceride production and repressing catabolic pathways, while in heart and muscle tissue, it partners with GATA4 and MEF2C to regulate genes essential for sarcomere and cytoskeletal organization during congenital morphogenesis. Dysregulation of SMARCD3 contributes to medulloblastoma dissemination, especially in Group 3 tumors through Reelin and H3K27 trimethylation, pancreatic cancer therapy resistance, abdominal aortic aneurysms, and poor outcomes across various solid tumors.

References
https://pubmed.ncbi.nlm.nih.gov/36653361/ https://pubmed.ncbi.nlm.nih.gov/17363140/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%